Roivant Sciences Ltd (NASDAQ:ROIV)’s traded shares stood at 0.69 million during the latest session, with the company’s beta value hitting 1.16. At the last check today, the stock’s price was $11.31, to imply an increase of 0.22% or $0.03 in intraday trading. The ROIV share’s 52-week high remains $13.06, putting it -15.47% down since that peak but still an impressive 22.81% since price per share fell to its 52-week low of $8.73.

Analysts have given a consensus recommendation of Buy for Roivant Sciences Ltd (ROIV), translating to a mean rating of 1.20. Of 7 analyst(s) looking at the stock, 0 analyst(s) give ROIV a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 7 recommend it as a Buy.

Roivant Sciences Ltd (NASDAQ:ROIV) trade information

After registering a 0.22% upside in the latest session, Roivant Sciences Ltd (ROIV) has traded red over the past five days. The 5-day price performance for the stock is 0.94%, and 5.07% over 30 days. With these gigs, the year-to-date price performance is -4.44%.

The extremes give us $12.5 and $20 for target low and target high price respectively. As such, ROIV has been trading -76.83% off suggested target high and -10.52% from its likely low.

ROIV Dividends

Roivant Sciences Ltd has its next earnings report out in July. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

The next major institution holding the largest number of shares is VIKING GLOBAL INVESTORS LP with 69.16 million shares, or about 9.3985% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $730.98 million.